Delayed AdvancementsGiven the tough funding environment and capital intensive nature of a F2–3 MASH Ph3 study, SGMT is deferring the pivotal advancement of denifanstat.
Financial ChallengesSagimet Biosciences reported a net loss of $18.2 million for the quarter, reflecting financial challenges.
Funding DependencyDosing for the Phase 3 MASH trial will only start upon securing sufficient financing, highlighting a financial dependency.